What Matters Most to Patients with NSCLC When Choosing Anticancer Treatments in China? A Best–Worst Scaling Study
Patient Preference and Adherence · 2026-03 · Volume 20 · 1-11
DOI: 10.2147/ppa.s584024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Patient Preference and Adherence, 2026-03. Verfasst von Jingyi Qiao und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Fudan University, Shanghai, People's Republic of China. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Public Health, Fudan University, Shanghai, People's Republic of China.
- National Health Commission Key Laboratory of Health Technology Assessment (Fudan University), Shanghai, People's Republic of China.
- Department of Teaching Management, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.
ORCID-Profile: Shimeng Liu, Yingyao Chen
Zitieren
APA
Qiao, J., Liu, S., Bao, S., Tao, Y., Zhao, J., & Chen, Y. (2026). What Matters Most to Patients with NSCLC When Choosing Anticancer Treatments in China? A Best–Worst Scaling Study. Patient Preference and Adherence, Volume 20, 1-11. https://doi.org/10.2147/ppa.s584024
Vancouver
Qiao J, Liu S, Bao S, Tao Y, Zhao J, Chen Y. What Matters Most to Patients with NSCLC When Choosing Anticancer Treatments in China? A Best–Worst Scaling Study. Patient Preference and Adherence. 2026;Volume 20:1-11. doi:10.2147/ppa.s584024
BibTeX
@article{Qiao2026,
author = {Qiao, Jingyi and Liu, Shimeng and Bao, Shiyi and Tao, Ying and Zhao, Jiaxin and Chen, Yingyao},
title = {What Matters Most to Patients with NSCLC When Choosing Anticancer Treatments in China? A Best–Worst Scaling Study},
journal = {Patient Preference and Adherence},
year = {2026},
volume = {Volume 20},
pages = {1--11},
doi = {10.2147/ppa.s584024}
}
EUVIMED